Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0044 • ACR Convergence 2020
Characterization of Racial Disparities in Rheumatoid Arthritis Treatment Choice and Location of Care
Elston He¹, Eli Cornblath², Pratyusha Yalamanchi³, Alexis Ogdie², Joshua Baker² and Michael George², ¹Synovium, Inc., Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Michigan Medicine, Ann Arbor, MI
Background/Purpose: Racial disparities in access to care and treatment regimens exist but remain poorly characterized in the rheumatoid arthritis (RA) patient population. Previous studies using…
Abstract Number: 0134 • ACR Convergence 2020
The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial
Sean McKenna¹, Laura Comber², Alan Donnelly³, Alexander Fraser⁴, Bente Appel Esbensen⁵ and Norelee Kennedy³, ¹University of Limerick, Mallow, Cork, Ireland, ²HIQA, Limerick, Limerick, Ireland, ³University of Limerick, Limerick, Limerick, Ireland, ⁴University College Limerick, Limerick, Limerick, Ireland, ⁵University of Copenhagen, Glostrup, Hovedstaden, Denmark
Background/Purpose: Poor sleep quality and reduced sleep duration are prevalent complaints in people with RA. These in turn may further deteriorate functional ability and reduce…
Abstract Number: 0159 • ACR Convergence 2020
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with…
Abstract Number: 0191 • ACR Convergence 2020
Increased Frequency of Lower Limb Arterial Obstruction in Rheumatoid Arthritis
Ahmed Oglah¹, Ali Hussein², Jose Felix Restrepo³, Carlos Lorenzo³, Agustin Escalante³ and Inmaculada Del Rincon³, ¹University of Texas Health Science Center at San Antonio/ Internal Medicine Residency program, San Antonio, TX, ²University of Texas Health Science Center at San Antonio/ Department of Internal Medicine/ Rheumatology, San Antonio, TX, ³University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Despite a high frequency of cardiovascular disease in rheumatoid arthritis (RA), peripheral arterial disease in RA has received little attention. The objective of the…
Abstract Number: 0207 • ACR Convergence 2020
Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Maureen Rischmueller³, Ricardo Blanco⁴, Ricardo Xavier⁵, Mark Howard⁶, Alan Friedman⁶, Yanna Song⁷ and Vibeke Strand⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ³The Queen Elizabeth Hospital and Univ of Adelaide, St Peters, South Australia, Australia, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy vs methotrexate (MTX) in a randomized, controlled…
Abstract Number: 0224 • ACR Convergence 2020
Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
Alvin Wells¹, Bochao Jia², Li Xie², Guillermo Valenzuela³, Edward C Keystone⁴, Zhanguo Li⁵, Amanda Quebe², Kirstin Griffing², Susan Otawa² and Boulos Haraoui⁶, ¹Aurora Rheumatology and Immunotherapy Center, Franklin, ²Eli Lilly and Company, Indianapolis, IN, ³Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic), ⁶Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The short-term efficacy of baricitinib was demonstrated previously.1,2 The objectives of this post-hoc analysis were to evaluate long-term efficacy of once-daily baricitinib 2 mg…
Abstract Number: 0240 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures
Roy Fleischmann¹, Karina Maslova², Henry Leher³, Amy Praestgaard² and Gerd Burmester⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Sanofi, Cambridge, MA, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: A proportion of adult patients with RA are refractory to TNF inhibitors (TNFi), and treatment with subsequent biologics may be associated with reduced response.…
Abstract Number: 0484 • ACR Convergence 2020
Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)‑associated enzyme with paraoxonase, lactonase, and arylesterase activities. PON1 contributes to the antioxidant properties of HDL, and…
Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Kjel Johnson¹, Rebecca Karos², Elisea Avalos-Reyes³, Fabio Casadio⁴, Michele Hamburger⁵ and Chiara Leprai⁴, ¹CVS Health, Lincoln, RI, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴CVS Health, New York, NY, ⁵Frances Hamburger Institute, Hauppauge, NY
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…
Abstract Number: 0749 • ACR Convergence 2020
Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
Isabella Wulur¹, David Boyle², Lin Zhang¹, Andrea Martin¹, Robert Benschop³ and Gary Firestein⁴, ¹Eli Lilly, Indianapolis, IN, ²UC San Diego, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: To better understand site-of-disease mechanisms in arthritis, the phenotypes and organization of synovial cells and infiltrates are critical. Conventional histology-based approaches are limited in…
Abstract Number: 0767 • ACR Convergence 2020
Anti-acetylated Protein Antibodies in Rheumatoid Arthritis (RA): Clues for the Starting Point of Autoantibody Responses in RA
Tineke van Wesemael¹, Nazike Salioska², Annemarie Dorjée¹, Thomas Huizinga¹, Annette van der Helm - van Mil³, René Toes¹ and Diane van der Woude¹, ¹Leiden university medical center, Leiden, Netherlands, ²leiden university medical center, Rotterdam, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies such as rheumatoid factor (RF) and anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-carbamylated…
Abstract Number: 0784 • ACR Convergence 2020
Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis
Jimeng Xue¹, Liling Xu¹, Fanlei Hu¹ and Yin Su², ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic)
Background/Purpose: The study aimed to investigate the expression and clinical significance of Tyro3TK on CD14+CD16+ and CD14+CD16- monocyte subsets and explore the effect of Tyro3TK…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 0817 • ACR Convergence 2020
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Geoffrey Littlejohn¹, Tegan Smith², Kathleen Tymms³, Peter Youssef⁴, Helen Cooley⁵, Sabina Ciciriello⁶, David Mathers⁷, Catherine OSullivan² and Hedley Griffiths⁸, ¹Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁴University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁵Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁸Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia
Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
Abstract Number: 0834 • ACR Convergence 2020
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Stefano Fiore¹, Lang Chen², Cassie Clinton², Huifeng Yun², Amy Praestgaard³, Kerri Ford³ and Jeffrey R Curtis², ¹Sanofi, Bridgewater, NJ, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Sanofi, Cambridge, MA
Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].